Vermillion (NASDAQ:VRML) Stock Crosses Above Two Hundred Day Moving Average of $0.73

Vermillion, Inc. (NASDAQ:VRML) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.73 and traded as high as $0.77. Vermillion shares last traded at $0.72, with a volume of 12,470 shares trading hands.

The company has a 50-day moving average of $0.65 and a 200-day moving average of $0.73. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.54 and a quick ratio of 4.53.

Vermillion (NASDAQ:VRML) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $1.29 million during the quarter. Vermillion had a negative net margin of 353.32% and a negative return on equity of 163.08%.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Vermillion by 145.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,984,250 shares of the company’s stock valued at $1,766,000 after acquiring an additional 1,177,152 shares in the last quarter. Calamos Advisors LLC acquired a new stake in shares of Vermillion in the 2nd quarter valued at about $712,000. Perkins Capital Management Inc. acquired a new stake in shares of Vermillion in the 3rd quarter valued at about $176,000. Russell Investments Group Ltd. bought a new stake in shares of Vermillion in the second quarter valued at about $278,000. Finally, Millennium Management LLC bought a new stake in shares of Vermillion in the third quarter valued at about $78,000. Institutional investors and hedge funds own 21.04% of the company’s stock.

Vermillion Company Profile (NASDAQ:VRML)

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Featured Story: Buy Rating

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit